# Aparna Thakur

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/aparna-thakur
Canonical HTML page: https://getbiobrief.com/entity/aparna-thakur

## Recent coverage (2 stories)

### Alport Syndrome Market to Hit 47% CAGR Through 2036 on Gene Therapy Pipeline
2026-07-27 09:04:39 · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Full story: https://getbiobrief.com/story/alport-syndrome-market-47-cagr-2036-bio

### PKU Market Set for Decade of Growth as Innovative Therapies Target Unmet Needs
2026-02-19 00:21:50 · Sentiment: Positive · Impact: 6/10 · Sources: 3

The global Phenylketonuria (PKU) market is projected to expand significantly through 2034, fueled by a robust pipeline of next-generation therapies and enhanced diagnostic screening. With the United States leading in diagnosed prevalence, major players like BioMarin, PTC Therapeutics, and Jnana are racing to address the metabolic limitations of current standard-of-care treatments.
Full story: https://getbiobrief.com/story/pku-market-growth-2034-innovative-therapies

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.